A Prospective, Randomized, Parallel Crossover Study Demonstrating Subject Wearability and Usability of the I-Port Injection Port

Inclusion Criteria: * Male and female subjects, 14-70 years of age, with type 1 and type 2 diabetes mellitus for a minimum of six (6) months * Subjects must be utilizing a regimen of at least two (2)injections daily of either Novolin®, Humulin®, NovoLog®, Humalog® or Apidra® and no more than one (1) injection of Lantus® daily using a standard syringe or insulin pen * Current regimen of intensified insulin therapy (defined as separate injections of basal and prandial insulin with at least three (3) insulin injections per day) for a minimum of three (3) months * Body Mass Index \<35 kg/m2 * HbA1c ≤ 10 % * If medications (other than oral anti-diabetic agents) in addition to insulin are taken at screening, the subject must be on a stable regimen as defined by continued use of the same dose of each medication for a period of at least three (3) months prior to study enrollment * Subjects must be willing to provide written informed consent Exclusion Criteria: * Use of Continuous Subcutaneous Insulin Infusion (CSII) at any time within the preceding three (3) months * History or current diagnosis of chronic diseases which in the view of the PI would interfere with adequate involvement in and completion of the requirements of the study * Use of short term or chronic steroids within two (2) months of entry into the study or likelihood that same might be required during the conduct of the study * Use of hydrochlorthiazide at doses \>25 mg daily * Use of beta-blocker drugs * Regular pr…